{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:17Z","timestamp":1790856377265,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.lfs.2021.119326","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T16:29:45Z","timestamp":1615307385000},"page":"119326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases"],"prefix":"10.1016","volume":"274","author":[{"given":"Danielle Paige","family":"Anthony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya S.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thasneema","family":"Rafic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.S. Satish","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119326_bb0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.lfs.2021.119326_bb0010","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2021.119326_bb0015","series-title":"Comparative physiology of the blood-brain barrier","first-page":"371","author":"Abbott","year":"1992"},{"key":"10.1016\/j.lfs.2021.119326_bb0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1152\/jappl.1985.58.6.1929","article-title":"O2 exchange between blood and brain tissues studied with 18O2 indicator-dilution technique","volume":"58","author":"Grieb","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.lfs.2021.119326_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2021.119326_bb0030","first-page":"57","article-title":"Duodopa pump treatment in patients with advanced Parkinson\u2019s disease","author":"Karlsborg","year":"2010","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.lfs.2021.119326_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1517\/17425247.2011.556616","article-title":"New non-oral drug delivery systems for Parkinson\u2019s disease treatment","volume":"8","author":"Md","year":"2011","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.lfs.2021.119326_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.med.57.121304.131442","article-title":"Current pharmacotherapy for Alzheimer\u2019s disease","volume":"57","author":"Lle\u00f3","year":"2006","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.lfs.2021.119326_bb0045","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1073\/pnas.041620798","article-title":"CA1-specific N-methyl-d-aspartate receptor knockout mice are deficient in solving a nonspatial transverse patterning task","volume":"98","author":"Rondi-Reig","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6075","key":"10.1016\/j.lfs.2021.119326_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science (New York, N.Y.)"},{"issue":"8","key":"10.1016\/j.lfs.2021.119326_bb0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.lfs.2021.119326_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/187152708784936608","article-title":"Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies","author":"Adibhatla","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.lfs.2021.119326_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0021-9150(98)00014-8","article-title":"HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data","volume":"138","author":"Crouse","year":"1998","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.lfs.2021.119326_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MJT.0b013e31814b17bf","article-title":"Targeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamole","volume":"16","author":"Weyrich","year":"2009","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.lfs.2021.119326_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2249.2005.02653.x","article-title":"Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients","volume":"139","author":"Chan","year":"2005","journal-title":"Clin. Exp. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2021.119326_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","article-title":"Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats","volume":"156","author":"Yang","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.lfs.2021.119326_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-009-1050-5","article-title":"Temozolomide in malignant gliomas: current use and future targets","volume":"64","author":"Villano","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119326_bb0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1750-3639.2003.tb00006.x","article-title":"Targeted molecular therapy of GBM","volume":"13","author":"Mischel","year":"2003","journal-title":"Brain Pathol."},{"key":"10.1016\/j.lfs.2021.119326_bb0095","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.lfs.2021.119326_bb0100","article-title":"The blood-brain barrier: an overview","author":"Ballabh","year":"2004","journal-title":"Structure, Regulation, and Clinical Implications"},{"key":"10.1016\/j.lfs.2021.119326_bb0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1469-7580.2002.00064.x","article-title":"Astrocyte-endothelial interactions and blood-brain barrier permeability","volume":"200","author":"Abbott","year":"2002","journal-title":"J. Anat."},{"key":"10.1016\/j.lfs.2021.119326_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/2045-8118-9-23","article-title":"Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation","author":"Luissint","year":"2012","journal-title":"Fluids and Barriers of the CNS"},{"key":"10.1016\/j.lfs.2021.119326_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/glia.22575","article-title":"Glial influence on the blood brain barrier","author":"Alvarez","year":"2013","journal-title":"GLIA"},{"key":"10.1016\/j.lfs.2021.119326_bb0120","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.neuron.2018.09.045","article-title":"Astrocytes integrate behavioral state and vascular signals during functional hyperemia","volume":"100","author":"Tran","year":"2018","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.lfs.2021.119326_bb0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbadis.2015.10.004","article-title":"Glial influences on BBB functions and molecular players in immune cell trafficking","volume":"1862","author":"Lecuyer","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.lfs.2021.119326_bb0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood\u2013brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119326_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.lfs.2021.119326_bb0140","doi-asserted-by":"crossref","DOI":"10.1124\/pr.57.2.4","article-title":"The blood-brain barrier\/neurovascular unit in health and disease","author":"Hawkins","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1715163517690745","article-title":"Dementia: what pharmacists need to know","volume":"150","author":"Duong","year":"2017","journal-title":"Canadian Pharmacists Journal"},{"key":"10.1016\/j.lfs.2021.119326_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119326_bb0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2021.119326_bb0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1503\/cmaj.151179","article-title":"An update on the diagnosis and treatment of Parkinson disease","volume":"188","author":"Rizek","year":"2016","journal-title":"Cmaj"},{"key":"10.1016\/j.lfs.2021.119326_bb0165","doi-asserted-by":"crossref","DOI":"10.2217\/epi.10.43","article-title":"Role of epigenetics in Alzheimers and Parkinsons disease","author":"Kwok","year":"2010","journal-title":"Epigenomics"},{"key":"10.1016\/j.lfs.2021.119326_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.31887\/DCNS.2004.6.3\/akorczyn","article-title":"Drug treatment of Parkinson\u2019s disease","volume":"6","author":"Korczyn","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2021.119326_bb0175","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: a double-blind, placebo-controlled, multicenter trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2021.119326_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy body dementias: dementia with lewy bodies and Parkinson disease dementia","volume":"22","author":"Gomperts","year":"2016","journal-title":"CONTINUUM Lifelong Learning in Neurology"},{"key":"10.1016\/j.lfs.2021.119326_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.lfs.2021.119326_bb0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies [8]","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119326_bb0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","article-title":"Frontotemporal dementia","volume":"35","author":"Olney","year":"2017","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.lfs.2021.119326_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125317739818","article-title":"Frontotemporal dementia: latest evidence and clinical implications","volume":"8","author":"Young","year":"2018","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"Suppl. 4","key":"10.1016\/j.lfs.2021.119326_bb0205","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.lfs.2021.119326_bb0210","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/neuonc\/nos208","article-title":"Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review","volume":"14","author":"Braganza","year":"2012","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14791\/btrt.2018.6.e4","article-title":"Risk of brain tumor induction from pediatric head CT procedures: a systematic literature review","volume":"6","author":"Sheppard","year":"2018","journal-title":"Brain Tumor Research and Treatment"},{"issue":"5","key":"10.1016\/j.lfs.2021.119326_bb0220","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3892\/ijo.2015.2908","article-title":"Mobile phone radiation causes brain tumors and should be classified as a probable human carcinogen (2A)","volume":"46","author":"Morgan","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2021.119326_bb0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-1-60327-492-0_14","article-title":"Epidemiology of brain tumors","volume":"472","author":"Ohgaki","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119326_bb0230","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.06.12","article-title":"Clinical presentation and epidemiology of brain tumors firstly diagnosed in adults in the emergency department: a 10-year, single center retrospective study","volume":"5","author":"Comelli","year":"2017","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.lfs.2021.119326_bb0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119326_bb0240","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119326_bb0245","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","author":"Arvanitis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2021.119326_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-26636-6","article-title":"Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a","volume":"8","author":"Tiwary","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119326_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.lfs.2021.119326_bb0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2014.00211","article-title":"Astrocytic modulation of blood brain barrier: perspectives on Parkinson\u2019s disease","volume":"8","author":"Cabezas","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2021.119326_bb0270","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/jcbfm.2011.197","article-title":"Neurological diseases in relation to the blood-brain barrier","volume":"32","author":"Rosenberg","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.lfs.2021.119326_bb0275","series-title":"Hypertensive Encephalopathy and the Blood-brain Barrier: Is d PKC a Gatekeeper? Find the Latest Version: Hypertensive Encephalopathy and the Blood-brain Barrier: Is \u03b4 PKC a Gatekeeper?","first-page":"17","volume":"vol. 118","author":"Chou","year":"2008"},{"key":"10.1016\/j.lfs.2021.119326_bb0280","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1046\/j.1471-4159.1996.67041688.x","article-title":"Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine","volume":"67","author":"Drion","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.119326_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fneng.2013.00007","article-title":"The blood-brain barrier: an engineering perspective","author":"Wong","year":"2013","journal-title":"Frontiers in Neuroengineering"},{"key":"10.1016\/j.lfs.2021.119326_bb0290","first-page":"1663","article-title":"The blood-brain barrier and cancer: transporters,treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"AACR"},{"key":"10.1016\/j.lfs.2021.119326_bb0295","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00496.2009","article-title":"Will the original glucose transporter isoform please stand up!","volume":"297","author":"Carruthers","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2021.119326_bb0300","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D","article-title":"Transporter-mediated permeation of drugs across the blood-brain barrier","volume":"89","author":"Tamai","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119326_bb0305","series-title":"Efflux Transport Systems for Drugs at the Blood\u2013Brain Barrier and Blood\u2013Cerebrospinal Fluid Barrier (Part 1)","author":"Kusuhara","year":"2001"},{"key":"10.1016\/j.lfs.2021.119326_bb0310","series-title":"Efflux Transport Systems for Drugs at the Blood\u2013Brain Barrier and Blood\u2013Cerebrospinal Fluid Barrier (Part 2)","author":"Kusuhara","year":"2001"},{"key":"10.1016\/j.lfs.2021.119326_bb0315","series-title":"The ABC of the Blood-Brain Barrier-Regulation of Drug Efflux Pumps","author":"Mahringer","year":"2011"},{"issue":"11","key":"10.1016\/j.lfs.2021.119326_bb0320","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D","article-title":"Transporter-mediated permeation of drugs across the blood-brain barrier","volume":"89","author":"Tsuji","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119326_bb0325","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","article-title":"Blood-brain barrier transport of therapeutics via receptor-mediation","volume":"24","author":"Jones","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0330","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herv\u00e9","year":"2008","journal-title":"AAPS Journal"},{"key":"10.1016\/j.lfs.2021.119326_bb0335","series-title":"Intrathecal Chemotherapy: Brain Tissue Profiles after Ventriculocisternal Perfusion","author":"Blasberg","year":"1975"},{"key":"10.1016\/j.lfs.2021.119326_bb0340","series-title":"Convection-enhanced Delivery of Macromolecules in the Brain","author":"Bobo","year":"1994"},{"key":"10.1016\/j.lfs.2021.119326_bb0345","doi-asserted-by":"crossref","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.lfs.2021.119326_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2012.01.004","article-title":"Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations","author":"Serwer","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0355","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"2","key":"10.1016\/j.lfs.2021.119326_bb0365","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jcp.55.2.158-a","article-title":"Brain drug targeting: the future of brain drug development: Pardridge W M. Cambridge University Press, 2001","volume":"55","author":"Kamphorst","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"4527","key":"10.1016\/j.lfs.2021.119326_bb0370","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1126\/science.7313698","article-title":"Site-specific, sustained release of drugs to the brain","volume":"214","author":"Bodor","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119326_bb0375","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2021.119326_bb0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2015.11.009","article-title":"Brain aging and Parkinson\u2019s disease: new therapeutic approaches using drug delivery systems","volume":"84","author":"Rodr\u00edguez-Nogales","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.lfs.2021.119326_bb0385","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1039\/C7NR00305F","article-title":"A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin","volume":"9","author":"Prabhu","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.lfs.2021.119326_bb0390","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(99)00062-9","article-title":"Targeted drug delivery via the folate receptor","author":"Sudimack","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2004.08.017","article-title":"Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate","author":"Yoo","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0405","doi-asserted-by":"crossref","DOI":"10.3402\/nano.v3i0.18496","article-title":"Utilizing the folate receptor for active targeting of cancer nanotherapeutics","author":"Zwicke","year":"2012","journal-title":"Nano Reviews"},{"key":"10.1016\/j.lfs.2021.119326_bb0410","series-title":"Physiology of the Blood\u2013Brain Barrier and Mechanisms of Transport Across the BBB","author":"Lalatsa","year":"2018"},{"key":"10.1016\/j.lfs.2021.119326_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","article-title":"Nanoparticle technology for drug delivery across the blood-brain barrier","volume":"28","author":"Lockman","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"4","key":"10.1016\/j.lfs.2021.119326_bb0425","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/156720107782151269","article-title":"Liposomal drug delivery systems: an update review","volume":"4","author":"Samad","year":"2007","journal-title":"Current drug delivery"},{"key":"10.1016\/j.lfs.2021.119326_bb0430","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/296151","article-title":"The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier","author":"Boado","year":"2011","journal-title":"Journal of Drug Delivery"},{"key":"10.1016\/j.lfs.2021.119326_bb0435","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of biologics across the blood\u2013brain barrier with molecular Trojan horse technology","author":"Pardridge","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.lfs.2021.119326_bb0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ics.2005.02.022","article-title":"Diphtheria toxin receptor-targeted brain drug delivery","volume":"1277","author":"Gaillard","year":"2005","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.lfs.2021.119326_bb0445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-59745-210-6_8","article-title":"2B-transTM technology: targeted drug delivery across the blood-brain barrier","volume":"437","author":"Gaillard","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119326_bb0450","article-title":"Drug treatment of epilepsy in adults","volume":"348","author":"Schmidt","year":"2014","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.lfs.2021.119326_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119326_bb0460","first-page":"5139","article-title":"Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo","volume":"62","author":"Zitzmann","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0465","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1805841","article-title":"The SR-B1 receptor as a potential target for treating glioblastoma","author":"Berney","year":"2019","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.lfs.2021.119326_bb0470","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2005.03463.x","article-title":"The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells","author":"Abulrob","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.119326_bb0475","article-title":"Passage of cytokines across the blood-brain barrier","author":"Banks","year":"1995","journal-title":"NeuroImmunoModulation"},{"key":"10.1016\/j.lfs.2021.119326_bb0480","doi-asserted-by":"crossref","first-page":"14608","DOI":"10.1039\/c2jm32398b","article-title":"Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles","volume":"22","author":"Wang","year":"2012","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.lfs.2021.119326_bb0485","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.addr.2010.07.009","article-title":"Nanoparticle-based theranostic agents","volume":"62","author":"Xie","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0490","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.maturitas.2011.12.015","article-title":"Nanotechnology for neurodegenerative disorders","volume":"73","author":"Re","year":"2012","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.lfs.2021.119326_bb0495","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2174\/138945011794815257","article-title":"Therapeutic and diagnostic applications of nanoparticles","volume":"12","author":"Youns","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.lfs.2021.119326_bb0500","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/nn501292z","article-title":"Precision nanomedicine in neurodegenerative diseases","volume":"8","author":"Goldsmith","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.lfs.2021.119326_bb0505","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF03188928","article-title":"Drug targeting with nanoparticles","volume":"19","author":"Kreuter","year":"1994","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.lfs.2021.119326_bb0515","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2021.119326_bb0520","first-page":"2310","article-title":"Perspectives on brain-targeting drug delivery systems article in current pharmaceutical biotechnology","volume":"13","author":"Ren","year":"2012","journal-title":"Ingentaconnect.Com."},{"key":"10.1016\/j.lfs.2021.119326_bb0525","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1039\/C5BM00383K","article-title":"Strategies for transporting nanoparticles across the blood-brain barrier","volume":"4","author":"Zhang","year":"2016","journal-title":"Biomaterials Science"},{"key":"10.1016\/j.lfs.2021.119326_bb0530","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","article-title":"Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer\u2019s disease mice","volume":"80","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119326_bb0535","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0356-z","article-title":"Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization","volume":"16","author":"S\u00e1nchez-L\u00f3pez","year":"2018","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.lfs.2021.119326_bb0540","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","article-title":"Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinsons disease","volume":"415","author":"Hu","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0545","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment","volume":"11","author":"Bi","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119326_bb0550","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","article-title":"A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease","volume":"277","author":"Qu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0555","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijpharm.2016.06.127","article-title":"Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-shell nanoparticles","volume":"510","author":"Wei","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0560","doi-asserted-by":"crossref","first-page":"16662","DOI":"10.1039\/C6NR05055G","article-title":"Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells","volume":"8","author":"Li","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.lfs.2021.119326_bb0565","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3109\/1061186X.2013.812094","article-title":"Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway","volume":"21","author":"Kuo","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119326_bb0570","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/acsabm.8b00502","article-title":"Synthetic polymer nanoparticles functionalized with different ligands for receptor-mediated transcytosis across the blood-brain barrier","volume":"1","author":"Lu","year":"2018","journal-title":"ACS Applied Biomaterials"},{"key":"10.1016\/j.lfs.2021.119326_bb0575","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.7150\/thno.18985","article-title":"Self-assembly of gold nanoparticles shows microenvironment-mediated dynamic switching and enhanced brain tumor targeting","volume":"7","author":"Feng","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2021.119326_bb0580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.colsurfb.2018.09.047","article-title":"Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model","volume":"173","author":"Lakkadwala","year":"2019","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0585","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/jpet.119.263566","article-title":"Use of a noninvasive brain-penetrating peptide-drug conjugate strategy to improve the delivery of opioid pain relief medications to the brain","volume":"374","author":"Eiselt","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2021.119326_bb0590","article-title":"Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo","volume":"23","author":"Lakkadwala","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119326_bb0595","doi-asserted-by":"crossref","first-page":"12609","DOI":"10.1021\/acsami.0c01514","article-title":"Delivery of temozolomide and N3-propargyl analog to brain tumors using an apoferritin nanocage, cite this","volume":"12","author":"Bouzinab","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2021.119326_bb0600","first-page":"117","article-title":"Bifunctional aptamer-doxorubicin conjugate crosses the blood-brain barrier and selectively delivers its payload to EpCAM-positive tumor cells","volume":"30","author":"Macdonald","year":"2020","journal-title":"Liebertpub.Com."},{"key":"10.1016\/j.lfs.2021.119326_bb0605","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.1985.tb07167.x","article-title":"Human blood? Brain barrier insulin receptor biologic drug development for the CNS view project","author":"Pardridge","year":"1985","journal-title":"Article in Journal of Neurochemistry"},{"key":"10.1016\/j.lfs.2021.119326_bb0610","series-title":"Insulin-binding Sites in the Rat Brain: In Vivo Localization to the Circumventricular Organs by Quantitative Radioautography* Vanadium and Peroxovanadium in Cell Signaling View Project","author":"Posner","year":"2015"},{"key":"10.1016\/j.lfs.2021.119326_bb0615","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.pharmtox.47.120505.105237","article-title":"Drug targeting to the brain","volume":"47","author":"de Boer","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2021.119326_bb0620","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","article-title":"Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor","volume":"17","author":"Coloma","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0625","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119326_bb0630","series-title":"Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI","first-page":"10891","article-title":"Insulin-coated gold nanoparticles as an effective approach for bypassing the blood-brain barrier","author":"Betzer","year":"2019"},{"key":"10.1016\/j.lfs.2021.119326_bb0635","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119326_bb0640","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006948027674","article-title":"Transferrin and transferrin receptor function in brain barrier systems","volume":"20","author":"Moos","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.lfs.2021.119326_bb0645","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-3806(86)90111-2","article-title":"Immunocytochemical distribution of transferrin and its receptor in the developing chicken nervous system","volume":"30","author":"Oh","year":"1986","journal-title":"Dev. Brain Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0650","series-title":"Anti-transferrin Receptor Antibody and Antibody-drug Conjugates Cross the Blood-brain Barrier (Drug Delivery\/Methotrexate)","author":"Friden","year":"1991"},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0655","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-4827(89)90293-0","article-title":"Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments","volume":"182","author":"Lesley","year":"1989","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.lfs.2021.119326_bb0660","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/jpet.104.082974","article-title":"Delivery of \u03b2-galactosidase to mouse brain via the blood-brain barrier transferrin receptor","volume":"313","author":"Zhang","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2021.119326_bb0665","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse","volume":"292","author":"Lee","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2021.119326_bb0670","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2008.08.021","article-title":"Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB)","volume":"71","author":"Ulbrich","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0675","doi-asserted-by":"crossref","unstructured":"J. Huwyler, D. Wu, W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci.. 93 (2002) 14164\u201314169. doi:https:\/\/doi.org\/10.1073\/pnas.93.24.14164.","DOI":"10.1073\/pnas.93.24.14164"},{"key":"10.1016\/j.lfs.2021.119326_bb0680","article-title":"Human blood-brain barrier transferrin receptor biologic drug development for the CNS view project","author":"Pardridge","year":"1987","journal-title":"Article in Metabolism"},{"key":"10.1016\/j.lfs.2021.119326_bb0685","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","article-title":"Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor","volume":"110","author":"Wiley","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119326_bb0690","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1471-4159.2002.01201.x","article-title":"High transcytosis of melanotransferrin (P97) across the blood-brain barrier","volume":"83","author":"Demeule","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.119326_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ics.2005.02.021","article-title":"Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier","author":"Gabathuler","year":"2005","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.lfs.2021.119326_bb0700","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X18772998","article-title":"A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model","author":"Thom","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.lfs.2021.119326_bb0705","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1359-6446(00)01594-4","article-title":"Folate-mediated targeting: from diagnostics to drug and gene delivery","volume":"6","author":"Leamon","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2021.119326_bb0710","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.biomaterials.2011.10.057","article-title":"Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat","volume":"33","author":"Cheng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119326_bb0715","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejps.2016.02.015","article-title":"A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration","volume":"88","author":"Xu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0720","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgn250","article-title":"Base excision repair of oxidative DNA damage and association with cancer and aging","volume":"30","author":"Maynard","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2021.119326_bb0725","doi-asserted-by":"crossref","first-page":"39633","DOI":"10.1021\/acsami.9b14659","article-title":"Folate receptor \u03b1-modified nanoparticles for targeting of the central nervous system","volume":"11","author":"Kuplennik","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2021.119326_bb0730","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1039\/C9NA00056A","article-title":"Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in the brain using a carbon nanosphere-cationic folate nanoconjugate","volume":"1","author":"Elechalawar","year":"2019","journal-title":"Nanoscale Advances"},{"key":"10.1016\/j.lfs.2021.119326_bb0735","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2014.10.047","article-title":"In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes","volume":"1594","author":"Candela","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0740","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.138.4.877","article-title":"A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier","volume":"138","author":"Dehouck","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.lfs.2021.119326_bb0745","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12031-010-9471-5","article-title":"CRM197-induced blood\u2013brain barrier permeability increase is mediated by upregulation of caveolin-1 protein","volume":"43","author":"Wang","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2021.119326_bb0750","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","article-title":"Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology","volume":"16","author":"Moura","year":"2019","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.lfs.2021.119326_bb0755","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119326_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2009.12.008","article-title":"Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo","author":"Huang","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.lfs.2021.119326_bb0765","article-title":"Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433)","author":"Kumari","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2021.119326_bb0770","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2008.10.016","article-title":"Lactoferrin-conjugated PEG\u2013PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations","volume":"134","author":"Hu","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0775","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.01381","article-title":"Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier","author":"Pan","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.lfs.2021.119326_bb0780","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119326_bb0785","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and design of peptides as a new drug delivery system for the brain","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2021.119326_bb0790","doi-asserted-by":"crossref","DOI":"10.1186\/s13568-019-0869-3","article-title":"Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood\u2013brain barrier and target glioma","author":"Ji","year":"2019","journal-title":"AMB Express"},{"key":"10.1016\/j.lfs.2021.119326_bb0795","doi-asserted-by":"crossref","unstructured":"A.J. Kastin, W. Pan, L.M. Maness, R.J. Koletsky, P. Ernsberger, Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor, Peptides. (1999). doi:https:\/\/doi.org\/10.1016\/S0196-9781(99)00156-4.","DOI":"10.1016\/S0196-9781(99)00156-4"},{"key":"10.1016\/j.lfs.2021.119326_bb0800","series-title":"Brain Targeted Drug Delivery System","article-title":"Receptor-mediated transportation through BBB","author":"Zhang","year":"2019"},{"key":"10.1016\/j.lfs.2021.119326_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2010.03.024","article-title":"Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis","author":"Tamaru","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119326_bb0810","doi-asserted-by":"crossref","DOI":"10.1172\/JCI119125","article-title":"Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels","author":"Golden","year":"1997","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.lfs.2021.119326_bb0815","article-title":"A leptin derived 30-amino-acid peptide modified pegylated poly-l-lysine dendrigraft for brain targeted gene delivery","author":"Liu","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119326_bb0820","doi-asserted-by":"crossref","DOI":"10.2217\/nnm.11.98","article-title":"Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?","author":"Tosi","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119326_bb0825","doi-asserted-by":"crossref","DOI":"10.3390\/toxins5061180","article-title":"Heparin-binding epidermal growth factor-like growth factor\/diphtheria toxin receptor in normal and neoplastic hematopoiesis","author":"Vinante","year":"2013","journal-title":"Toxins"},{"key":"10.1016\/j.lfs.2021.119326_bb0830","doi-asserted-by":"crossref","DOI":"10.1007\/s10571-010-9496-x","article-title":"Diphtheria toxin mutant CRM197-mediated transcytosis across blood-brain barrier in vitro","author":"Wang","year":"2010","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2021.119326_bb0835","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17425240902806383","article-title":"Differential receptor-mediated drug targeting to the diseased brain","volume":"6","author":"Rip","year":"2009","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.lfs.2021.119326_bb0840","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5b00446","article-title":"Exploiting bacterial pathways for BBB crossing with PLGA nanoparticles modified with a mutated form of diphtheria toxin (CRM197): in vivo experiments","author":"Tosi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2010.11.014","article-title":"Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain","author":"van Rooy","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2014.07.003","article-title":"Cardiolipin-incorporated liposomes with surface CRM197 for enhancing neuronal survival against neurotoxicity","author":"Kuo","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119326_bb0860","doi-asserted-by":"crossref","DOI":"10.3109\/1061186X.2010.492523","article-title":"Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles","author":"Chen","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119326_bb0865","doi-asserted-by":"crossref","DOI":"10.1021\/mp100238j","article-title":"Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery","author":"Zhan","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2021.119326_bb0870","article-title":"Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand","author":"Zhan","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.lfs.2021.119326_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2012.02.022","article-title":"Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo","author":"Zhan","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0880","doi-asserted-by":"crossref","DOI":"10.1021\/bi00109a020","article-title":"Structure-function relationships of curaremimetic neurotoxin loop 2 and of a structurally similar segment of rabies virus glycoprotein in their interaction with the nicotinic acetylcholine receptor","author":"Lentz","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2021.119326_bb0885","article-title":"A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery","author":"Wei","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.lfs.2021.119326_bb0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21144918","article-title":"Allosterism of nicotinic acetylcholine receptors: therapeutic potential for neuroinflammation underlying brain trauma and degenerative disorders","volume":"21","author":"Mitra","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119326_bb0895","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/bph.14209","article-title":"Nicotinic acetylcholine receptors","volume":"175","author":"Wonnacott","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119326_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119326_bb0905","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1039\/C4NR02776K","article-title":"Designing the nanobiointerface of fluorescent nanodiamonds: highly selective targeting of glioma cancer cells","volume":"7","author":"Slegerova","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.lfs.2021.119326_bb0910","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/0008-5472.CAN-14-1540","article-title":"Treatment of invasive brain tumors using a chain-like nanoparticle","volume":"75","author":"Peiris","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0915","series-title":"Herbal Drugs: Ethnomedicine to Modern Medicine","first-page":"221","article-title":"Novel leads from herbal drugs for neurodegenerative diseases","author":"Bhatnagar","year":"2008"},{"key":"10.1016\/j.lfs.2021.119326_bb0920","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1078-0432.CCR-19-1834","article-title":"Ultrasmall core-shell silica nanoparticles for precision drug delivery in a high-grade malignant brain tumor model","volume":"26","author":"Juthani","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119326_bb0925","doi-asserted-by":"crossref","DOI":"10.3390\/cells4020178","article-title":"Scavenger receptor structure and function in health and disease","author":"Zani","year":"2015","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2021.119326_bb0930","doi-asserted-by":"crossref","DOI":"10.1046\/j.1471-4159.2001.00100.x","article-title":"Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E","author":"Goti","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.119326_bb0935","doi-asserted-by":"crossref","DOI":"10.3109\/10611860903548354","article-title":"Biopharmaceutical drug targeting to the brain","author":"Pardridge","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119326_bb0940","doi-asserted-by":"crossref","DOI":"10.3109\/02652048.2012.692491","article-title":"Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)","author":"Kreuter","year":"2013","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.lfs.2021.119326_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2006.12.012","article-title":"Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain","author":"Kreuter","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119326_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2013.01.018","article-title":"The effects of lobeline on \u03b14\u03b22* nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats","author":"Hillmer","year":"2013","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.lfs.2021.119326_bb0955","doi-asserted-by":"crossref","DOI":"10.3390\/antib8020027","article-title":"Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases","author":"B\u00e9langer","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.lfs.2021.119326_bb0960","doi-asserted-by":"crossref","DOI":"10.1096\/fj.01-0343fje","article-title":"Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium","author":"Muruganandam","year":"2002","journal-title":"The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.lfs.2021.119326_bb0965","doi-asserted-by":"crossref","DOI":"10.1002\/bip.22928","article-title":"Phage display as a tool to discover blood\u2013brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model","author":"D\u00edaz-Perlas","year":"2017","journal-title":"Biopolymers"},{"key":"10.1016\/j.lfs.2021.119326_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.ics.2005.02.024","article-title":"Single domain antibodies as blood-brain barrier delivery vectors","author":"Abulrob","year":"2005","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.lfs.2021.119326_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/0165-5728(95)00148-4","article-title":"The influence of cytokines on the integrity of the blood-brain barrier in vitro","author":"de Vries","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.lfs.2021.119326_bb0980","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1535-7163.MCT-08-0853","article-title":"Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model","volume":"8","author":"Madhankumar","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2021.119326_bb0985","doi-asserted-by":"crossref","first-page":"27162","DOI":"10.1039\/C7RA03208K","article-title":"Overcoming the blood-brain barrier for glioma-targeted therapy based on an interleukin-6 receptor-mediated micelle system","volume":"7","author":"Shi","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2021.119326_bb0990","doi-asserted-by":"crossref","first-page":"58823","DOI":"10.18632\/oncotarget.19221","article-title":"Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2021.119326_bb0995","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/IJN.S243223","article-title":"Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive revie","volume":"15","author":"Li","year":"2020","journal-title":"Int. J. Nanomedicine"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521003118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521003118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:44:08Z","timestamp":1758401048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521003118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":199,"alternative-id":["S0024320521003118"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119326","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119326"}}